Companies › Regenerative Ocular Immunobiologics
1 active drug program in 2 registered trials: 1 Phase 3, 1 Phase 1; Immunology, Ophthalmology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| d-MAPPS™ Ophthalmic Solution unclear - preservative-free ophthalmic immunobiologic solution | – | Phase 3 | oGVHD; oGHVD | Dec 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06852768 | d-MAPPS™ Ophthalmic Solution | Phase 1 | oGHVD | Ophthalmology | Dec 2026 |
| NCT07776210 | d-MAPPS™ Ophthalmic Solution | Phase 3 | oGVHD | Immunology | Mar 2027 |
No annotated target.
–
Doron Therapeutics UnicoCell Biomed medac ALK-Abelló Kolon TissueGene
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.